|
|
Transcode Therapeutics Inc (NASDAQ: RNAZ) |
|
|
|
Transcode Therapeutics Inc 's Working Capital Per Sales
RNAZ's Working Capital and Revenue growth
Select the Comparisons :
|
|
Select the Ratio:
|
Working Capital Per Revenue▼
|
Working Capital Per Revenue▼
|
RNAZ Working Capital Per Revenue |
(Mar 31 2025) I. Quarter |
(Dec 31 2024) IV. Quarter |
(Sep 30 2024) III. Quarter |
(Jun 30 2024) II. Quarter |
(Mar 31 2024) III. Quarter |
Y / Y Working Capital Change |
138.76 % |
311.76 % |
-59.02 % |
-17.43 % |
- |
Y / Y Revenue Change |
- |
- |
- |
- |
- |
Working Capital Per Revenue |
- |
- |
- |
- |
- |
Working Capital Per Revenue Ranking |
# |
# |
# |
# |
# |
Seq. Working Capital Change |
140.14 % |
178.31 % |
30.23 % |
-72.57 % |
314.14 % |
Seq. Revenue Change |
- |
- |
- |
- |
- |
Comment on RNAZ's Working Capital Per Revenue in the first quarter 2025 |
Transcode Therapeutics Inc 's Working Capital Per Revenue sequentially grew to 314.14 during the Q1 2025, above the company average.
Within Healthcare sector Transcode Therapeutics Inc has achieved the lowest Working Capital Per Revenue. While Working Capital Per Revenue remained unchanged in the Q1 2025 relative to the prior quarter at no. .
|
Working Capital Per Revenue Ranking |
Within: |
No. |
Industry |
# |
Sector |
# |
S&P 500 |
# |
Working Capital Per Revenue Statistics |
High |
Average |
Low |
0 |
0 |
0 | |
|
|
Companies with similar Average Working Capital Per Revenue for 12 months ending Mar 31 2025, within Healthcare Sector | Working Capital Per Revenue |
|
Date modified: 2025-06-14T14:51:48+00:00
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com